相关实验视频

Updated: Jul 16, 2025

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

针对儿科大脑瘤的基于induximod的化疗免疫疗法:首次对儿童进行I期试验

Theodore S Johnson^1,2, Tobey J MacDonald³, Rafal Pacholczyk⁴

¹Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.

|September 16, 2023

概括

作为一种胺2,3-二氧化酶 (IDO) 抑制剂的induximod在治疗儿科复发性脑瘤方面表现有前途. 组合疗法耐受良好,并显示出令人鼓舞的生存益处,支持进一步的临床试验.

科学领域:

儿科瘤学儿科瘤学
癌症免疫学癌症免疫学
药理学药理学是指药理学的学科.

背景情况:

复发性脑瘤是儿童癌症死亡率的主要原因.
氨酸2,3-二氧化酶 (IDO) 是一种代谢检查点,可以抑制抗瘤免疫力.
针对IDO提出了一个潜在的策略,以提高癌症治疗的疗效.

研究的目的:

评估因多克西莫德与重复性脑瘤儿童的化疗或放射治疗结合的安全性和耐受性.
为了确定INDOXIMOD的最佳儿科剂量.
探索基于印多克西莫德的治疗的初步疗效和免疫效应.

主要方法:

一期临床试验 (NCT02502708) 涉及患有复发性脑瘤或新诊断的扩散内在孔丁质瘤 (DIPG) 的儿童.
用于因多克西莫德与泰莫索洛米德或息性辐射相结合的剂量检测臂.
采集血液样本用于单细胞RNA测序和T细胞受体测序.

主要成果:

印度克西莫德耐受性良好,确定的儿科剂量为19.2 mg/kg每天两次.
复发性疾病的平均整体存活时间为13.3个月,DIPG的平均总生存时间为14.4个月.
客观反应的患者的中位寿命超过3倍 (25.2个月) 与没有反应的患者 (7.3个月) 相比.
单细胞测序揭示了新的循环CD8T细胞克隆类型,具有效应体表型.

结论:

在儿童脑瘤患者中,因多克西莫德可以安全地与化疗和放射治疗结合使用.
初步的疗效数据表明,印克西莫德对治疗儿科脑瘤具有前景.
这些发现支持Indoximod进入II/III期临床试验.

关键词:

在 IDO IDO 里面.大脑癌症大脑癌症免疫疗法免疫疗法印度克西莫德 (Indoximod) 是一种儿科儿科儿科

更多相关视频

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...